Literature DB >> 23970651

Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.

Shui Shan Lee1, Kin Wang To, Man Po Lee, Ngai Sze Wong, Denise P C Chan, Patrick C K Li, Siu Wai Cheung, Raphael C Y Chan.   

Abstract

Seventy-two adult Chinese HIV-positive treatment-naïve patients were recruited in a study to evaluate prospectively the associations between CYP2B6 516 G/T polymorphisms and sleep quality following treatment with an efavirenz-based regimen. Overall, the patients gave an allelic frequency of 0.3 for CYP2B6 516 T, and a genotype frequency of 9.4% for TT. Compared to GG, GT gave a higher median value of plasma efavirenz level at four weeks (3.77 mg/L vs 2.59 mg/L, p < 0.001) and 12 months (3.57 mg/L vs 2.97 mg/L, p = 0.026). Using generalised estimating equations analysis to track the variance over time, there was poorer Pittsburgh Sleep Quality Index in GT compared to GG, while GT was associated with a higher efavirenz level of >4 mg/L. There was however no difference in the component sleep scores nor was there direct association between sleep quality and plasma efavirenz levels. The results suggested that CYP2B6 genotype was associated with different patterns of sleep problems, further investigation of which is warranted with the objective of optimizing therapy with efavirenz-based regimens.

Entities:  

Keywords:  AIDS; CYP2B6; HIV; Pittsburgh sleep quality index; antiretroviral therapy; efavirenz; pharmacogenetics; sleep quality; therapeutic drug monitoring

Mesh:

Substances:

Year:  2013        PMID: 23970651     DOI: 10.1177/0956462413498581

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  4 in total

1.  Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.

Authors:  Sabina Mugusi; Eliford Ngaimisi; Mohammed Janabi; Ferdinand Mugusi; Omary Minzi; Eric Aris; Muhammad Bakari; Leif Bertilsson; Juergen Burhenne; Eric Sandstrom; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2018-07-12       Impact factor: 2.953

2.  Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV.

Authors:  K H Hui; S S Lee; T N Lam
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-04-06

3.  Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.

Authors:  Francoise Pinillos; Collet Dandara; Marelize Swart; Renate Strehlau; Louise Kuhn; Faeezah Patel; Ashraf Coovadia; Elaine Abrams
Journal:  BMC Infect Dis       Date:  2016-02-02       Impact factor: 3.090

4.  An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.

Authors:  Marelize Swart; Jonathan Evans; Michelle Skelton; Sandra Castel; Lubbe Wiesner; Peter J Smith; Collet Dandara
Journal:  Front Genet       Date:  2016-01-07       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.